# Aribulin Combined With Carboplatin and Bevacizumab in the Treatment of Ovarian Cancer

> **NCT05965141** · PHASE1,PHASE2 · UNKNOWN · sponsor: **Second Affiliated Hospital of Guangzhou Medical University** · enrollment: 38 (estimated)

## Conditions studied

- Ovarian Cancer

## Interventions

- **DRUG:** Aribulin;carboplatin;bevacizumab

## Key facts

- **NCT ID:** NCT05965141
- **Lead sponsor:** Second Affiliated Hospital of Guangzhou Medical University
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-08-01
- **Primary completion:** 2025-04-01
- **Final completion:** 2025-06-01
- **Target enrollment:** 38 (ESTIMATED)
- **Last updated:** 2023-07-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05965141

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05965141, "Aribulin Combined With Carboplatin and Bevacizumab in the Treatment of Ovarian Cancer". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT05965141. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*